Slide 1 of 10
Slide 1 - Title Slide
The New Drug Development Cycle
Understanding the Stages, Incentives, and Regulatory Requirements in Pharmaceutical Development
The Drug Development Cycle: Stages, Incentives & Regulations
Generated from prompt:
Create a detailed PowerPoint presentation based on the uploaded document 'New Drug Development Cycle'. Slides should cover: overview (cost, timeline, success rates), Pre‑Discovery/Drug Discovery methods and incentives (NIH grants, SBIR/STTR, Orphan Drug Act), Pre‑Clinical stage (IACUC approval, in vitro vs in vivo testing, pharmacology & toxicology, GLP principles, dosage formulation, ADME studies, GMP manufacturing and the 5 P’s, IND application components), Clinical Development (trial protocol, participant selection, Phases 1–3 with sample sizes and goals, FDA expedited programs like Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, and orphan drug incentives), FDA Approval process (NDA/BLA submission, review categories, Hatch‑Waxman Act, patent term extension), and Post‑Marketing Monitoring (FAERS and safety surveillance). Include clear diagrams or process flow slides and a final summary slide.
Explore the pharmaceutical drug development lifecycle, from discovery and pre-clinical testing to clinical trials, FDA approvals, expedited pathways, and post-market surveillance. Covers costs, success rates, funding incentives like SBIR/STTR and the
April 29, 202610 slides
Slide 2 of 10
Slide 2 - Agenda
- Development Overview: Costs and Success Rates
- Early Research: Discovery and Funding Incentives
- Pre-Clinical Development: Testing and Safety Standards
- Clinical Trials: Phases and Expedited FDA Pathways
- FDA Approval and Post-Market Surveillance
Slide 3 of 10
Slide 3 - Development Overview: The Challenge
- 2.6B USD: Estimated Cost
- 10-15 Yrs: Total Timeline
- 10-15%: Success Rate
Slide 4 of 10
Slide 4 - Pre-Discovery and Drug Discovery
- Early discovery relies on basic research often supported by NIH grants.
- SBIR and STTR programs provide critical non-dilutive funding for small businesses to innovate.
- Orphan Drug Act incentivizes research into rare diseases via tax credits and market exclusivity.
- Target identification and validation are the foundational steps in the drug discovery pipeline.
---
Photo by Logan Voss on Unsplash
Slide 5 of 10
Slide 5 - Pre-Clinical Stage Workflow
| Step | Key Activities | Regulatory Requirement |
|---|---|---|
| Testing Strategy | In vitro vs in vivo experiments | IACUC Approval |
| Safety & Efficacy | Pharmacology and toxicology studies | GLP Principles adherence |
| Formulation | Dosage development & ADME studies | GMP Compliance (5 P's) |
| Submission | Compiling safety/efficacy data | IND Application Filing |
---
Photo by CDC on Unsplash
Slide 6 of 10
Slide 6 - Clinical Development Phases
Phase 1: Clinical Trials Part 1 Small group (20-100), focusing on safety and dosage. Phase 2: Clinical Trials Part 2 Medium group (100-500), testing efficacy and side effects. Phase 3: Clinical Trials Part 3 Large group (1,000-5,000+), verifying efficacy against standard treatments.
Slide 7 of 10
Slide 7 - FDA Expedited Programs
- Fast Track: Facilitates development for serious conditions.
- Breakthrough Therapy: Intensive guidance for drugs with substantial improvement.
- Accelerated Approval: Allows approval based on surrogate endpoints.
- Priority Review: Shortens standard FDA review time to 6 months.
- Orphan Drug Incentives: Enhanced exclusivity periods for rare disease therapies.
Slide 8 of 10
Slide 8 - FDA Approval Process
- NDA (New Drug Application) or BLA (Biologics License Application) submission.
- FDA review categories: Standard vs. Priority review.
- Hatch-Waxman Act: Balances generic competition and brand name incentives.
- Patent term extension: Restores time lost during the regulatory approval process.
Slide 9 of 10
Slide 9 - Post-Marketing Monitoring
- FAERS (FDA Adverse Event Reporting System) for public reporting.
- Post-marketing safety surveillance to monitor long-term effects.
- Risk Evaluation and Mitigation Strategies (REMS) if necessary.
- Continuous monitoring ensures ongoing benefit-risk profile assessment.
---
Photo by Tim Cooper on Unsplash
Slide 10 of 10
Slide 10 - Summary
Summary: Navigating the Drug Development Lifecycle
The journey from lab bench to patient bedside is complex, costly, and heavily regulated. Success requires scientific rigor, strategic funding, and alignment with FDA pathways.
Discover More Presentations
Explore thousands of AI-generated presentations for inspiration
Powered by AI
Create Your Own Presentation
Generate professional presentations in seconds with Karaf's AI. Customize this presentation or start from scratch.